Contraception
Volume 78, Issue 2 , Pages 136-142, August 2008

Increasing intrauterine contraception use by reducing barriers to post-abortal and interval insertion☆

  • Suzan Goodman

      Affiliations

    • University of California, San Francisco, San Francisco, CA 94110, USA
    • Corresponding Author InformationCorresponding author. University of California, San Francisco, CA 94110. Tel.: +1 415 202 4679; fax: +1 415 206 8387.
    • ,
  • Sarah K. Hendlish

      Affiliations

    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA
    • ,
  • Courtney Benedict

      Affiliations

    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA
    • ,
  • Matthew F. Reeves

      Affiliations

    • University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    • Magee-Women's Research Institute, Pittsburgh, PA 15261, USA
    • ,
  • Madeline Pera-Floyd

      Affiliations

    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA
    • ,
  • Anne Foster-Rosales

      Affiliations

    • University of California, San Francisco, San Francisco, CA 94110, USA
    • Planned Parenthood Golden Gate, San Francisco, CA 94109, USA

Received 4 August 2007; received in revised form 4 March 2008; accepted 13 March 2008. published online 19 June 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Financial support for this study was provided by FEI Women's Health (now DuraMed), producers of Paragard® T380A intrauterine copper contraceptive, who sponsored a Staff Training Pilot at Planned Parenthood Golden Gate (part of the intervention study). Ms. Hendlish is concurrently a research consultant for Berlex, Inc (now Bayer Health Care, Inc.), producers of Mirena® levonorgestrel-releasing intrauterine system.

PII: S0010-7824(08)00134-0

doi:10.1016/j.contraception.2008.03.008

Contraception
Volume 78, Issue 2 , Pages 136-142, August 2008

Article Tools

* Image Usage & Resolution